EliteTrading

$SPX $SPY Beautiful. Anyone else catch this? Gap below .. 655 key support. 660 key resistance. Bearish still till that resistance breaks. $QQQ $SQQQ $NVDA

@traderjon01 Industry is gaining traction and they have a first mover advantage here. Cool stuff!

$ARTL if volume continues we can see a move towards 5.84-5.85 before next resistance 👀 🔥 ART27.13, was originally developed by AstraZeneca ( $AZN ). So ties to big pharma built in. 🔥 ART27.13 for Glaucoma is fully funded by a third party. 🔥Artelo works closely with Professor Saoirse O'Sullivan, who is a leading global expert in cannabinoid and lipid-signaling medicine. 🔥Noteable institutional investors: UBS Asset Management, Two Sigma Investments, Vanguard Group, and Geode Capital Management. 🔥 Powerhouse board members: ✨Connie Matsui (Chair): Former Biogen VP. ✨Dr. Douglas Blayney: Former President of ASCO (top oncology authority)!! ✨Gregory Gorgas (CEO): Ex-Biogen executive. Disclaimer: tinyurl.com/traderjon01-ar… #advertisement ~ Paid $400 cash by a third party on 3/25/2026 for this promotion. I don't own any shares. Penny stocks are extremely high risk and volatile — NFA. Do your own due diligence. ~

@traderjon01 I like this name too!

Yeah swinging $DOMH and added to Roth as well. I did some quick math. They invested roughly $35m in SpaceX/XAI around $260 a share (just using rough timeframe of when they filed the 10k) That would be 135k shares The shares are now worth $114M What an investment! 🔥 $VCX me!

@traderjon01 Yes, especially with this float!

@EliteGainzTrade Huge potential!

📰 $ARTL TODAY’S NEWS, QUICK BREAKDOWN. ▪️ Entering $16.3B glaucoma market. Expands beyond current pipeline into a major new vertical.  ▪️ Fully funded clinical study secured. Third-party backed, means no direct cost to shareholders. ▪️ ART27.13 advancing into glaucoma. Same drug now targeting multiple indications. Thoughts: New market + funded study + real clinical progress! They are an early stage biotech with multiple catalysts .. and a LOW float that can gain traction fast. A #CBD name to watch, as they target a $100B market! Peers - $IMNN $ITRM $ATON $BFRI $LIAN $JAGX $CNSP $XRTX $SNOA $IGC $ZYNE $ACAD Communicated-Disclaimer- tinyurl.com/yyvaf8p6

$SPX $SPY H&S .. 660 is key 🔑 I'm bearish until we break and hold that. Over 660 it could get wild, but ... $QQQ $NVDA

@JohnLoc18 H&S 👀

I’ll try again, $SPY divergence right here, target 654-653 by end of day. Nfa.

@JohnLoc18 Yeah, nonstop rejections on higher time frames. It's too early for bulls to get excited, I've been saying this for weeks.

$SPX $SPY isn't bullish yet. I said last week that 660 break/hold is key. Multiple bear flags and rejections. $QQQ $NVDA $AAPL

$SPX $SPY Gap still.

@cameron_doproxy How is it a scam? Legit been using it daily for 2 years for free. It's cool if you don't want to capitalize.

@EliteGainzTrade another algo scam

$SPX $SPY Our #Algo will be live streamed FREE on Youtube soon. Eeeeeasy money. Look at our 3 entries. 🤑🔥 Follow for the link! $AAPL $WMT $NVDA $MSFT

@MomentumScans Thin float, this one could gain traction again fast.

✅ $ARTL Reversal watch . Just locked in a fully funded clinical study for ART27.13 in glaucoma — expanding into the massive $16.3B market. ✅ Ethics & MHRA approved ✅ Led by world-renowned expert ✅ First patients Q2 2026 ✅ Pipeline diversification with strong momentum (+50% surge on news) ✅ Watch for reversal after yesterdays pullback news-events/press-releases/detail/178/artelo-announces-third-party-fully-funded-clinical-study-agreement-to-evaluate-art27-13-in-glaucoma-patients Advertisement disclaimer in linktree .

@MomentumScans Yes! Bounce and sold off a bit, but potential here with more inflow on this low float

@EliteGainzTrade Markets challenging it today but it wants to bounce ! Likely undervalued with the latest news

News today with a pop, and now gap has filled. Watch for volume inflow and a continuation. 📈 $ARTL FULLY FUNDED STUDY + CLINICAL MOMENTUM BUILDING. Artelo Biosciences is stacking multiple bullish catalysts with its insane pipeline! 🔬 Clinical Progress: ART26.12 (pain program) ▪️ Positive Phase 1 human data ▪️ Favorable safety + dosing profile ⏳️ Moving toward next-stage trials in 2026 ART27.13 (cancer cachexia) ▪️ Positive Phase 2 interim results ▪️ Improved body weight + activity vs placebo ▪️ Large unmet need in oncology space 💰 NEW CATALYST: FULLY FUNDED GLAUCOMA STUDY Third party funded clinical study announced, expanding pipeline into $16B+ glaucoma market.No funding risk for this program. 🧠 CBD BREAKTHROUGH ANGLE (ART12.11) Proprietary pharma grade CBD candidate which improved bioavailability vs standard CBD.. now positioned for clinical trials! My Thoughts: Multiple opportunitiesin a massive and growing industry from (pain, cancer, CBD, glaucoma)! Positive clinical data across programs + FULLY funded, so LOW dilution risk. News Link: elite.finviz.com/news/320044/ar…⁠ Peers - $IMNN $ITRM $ATON $BFRI $LIAN $JAGX $CNSP $XRTX $SNOA $IGC $ZYNE $ACAD Communicated-Disclaimer- tinyurl.com/yyvaf8p6

@TheShortSqueezy Super cool image that depicts what this company is doing. Revenue and Profit climbing, but a low market cap.

$BNZI: Powering the Next Generation of AI Driven Marketing 📈 Banzai International is a MarTech SaaS company building an AI-driven platform for video, webinars, and customer engagement through strategic acquisitions. Latest News / Milestones 🔸 Transformational acquisition: BNZI reached a deal to acquire ConnectAndSell assets, a profitable AI sales acceleration 🔸 Revenue inflection: The deal is expected to more than double annual revenue, adding $15M+ in topline 🔸 AI expansion: Adds real-time sales engagement + AI capabilities, strengthening the platform 🔸 Strong prior growth: BNZI recently reported 163% YoY revenue growth Key Catalysts ⏳ Revenue step change from ConnectAndSell integration ⏳ Expansion into AI powered sales acceleration alongside marketing ⏳ Margin expansion potential from profitable acquired assets 🗓️March 31 conference call (Q4 2025 results, initiatives, and forward milestones) With the global MarTech and digital marketing market projected to exceed $500B+, BNZI is targeting a massive and rapidly expanding opportunity. Communcated Disclaimer: tinyurl.com/Therealshortsq… Sector Peers: $ZM $MSFT $GOOGL $DOCU $ADBE $TEAM $CRM $SHOP $NOW $TWLO

@JulesTradesInc Hot 🔥

$CVX 📊 Setup Overview ▪️ Clear bullish channel forming ▪️ Consistent higher highs + higher lows ▪️ Volume picking up on moves higher ▪️ Riding above key moving averages 🎯 Trade Plan ▪️ Key Level: $200 must hold ▪️ Upside Targets: $215 - $225 ▪️ Bias: Bullish continuation $SPX $QQQ $NVDA $SPY

🚨 Noteable charts with strength to track into end of day. $PAYS $MKDW $SIDU

🚨 Elite Market Momentum Snapshot 🚀 Top Gainers $RMSG $ROMA $PAYS $MKDW $SIDU $BZAI 💎 New Highs $ROMA $ELVN $SATL $MPTI 📊 Market Snapshot ▪️ $SPY → $660.9 (+1.9%) ▪️ Gold #Gold → $2,180 (+0.4%) ▪️ Silver #Silver → $24.5 (+0.6%) ▪️ Oil (WTI) → $81.5 (+0.8%) ▪️ Bitcoin #Bitcoin → $67,000 (+2.1%)